Comparative Pharmacology
Head-to-head clinical analysis: METHOCARBAMOL versus RELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOCARBAMOL versus RELA.
METHOCARBAMOL vs RELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
Adults: 250-350 mg orally 3-4 times daily.
None Documented
None Documented
Clinical Note
moderateMethocarbamol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone propionate."
Clinical Note
moderateMethocarbamol + Venlafaxine
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine."
Clinical Note
moderateMethocarbamol + Nefazodone
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone."
Clinical Note
moderateTerminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation.
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Methocarbamol + Stiripentol
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol."